Table 2.
Patient and tumor characteristics in ATRX mutated vs intact cases
| ATRX mutated | ATRX intact | |
|---|---|---|
| Total n | 9 | 39 |
| Age at diagnosis, year (median, range) | 45 (23-72) | 45 (16-73) |
| Male, n (%) | 6 (67) | 27 (69) |
| Aggressive pituitary tumors, n (%) | 4 (44) | 26 (67) |
| Pituitary carcinomas, n (%) | 5 (56) | 13 (33) |
| Tumor subtypes (IHC) | ||
| Corticotroph (n = 22) | 7 | 15 |
| PC (n = 12) | 4 | 8 |
| APT (n = 10) | 3 | 7 |
| Lactotroph (n = 15) | 1 | 14 |
| PC (n = 3) | 0 | 3 |
| APT (n = 12) | 1 | 11 |
| Somato/lactotroph (n = 2) | 1 | 1 |
| PC (n = 1) | 1 | 0 |
| APT (n = 1) | 0 | 1 |
| Other subtypesa (n = 9) | 0 | 9 |
| PC (n = 2) | 0 | 2 |
| APT (n = 7) | 0 | 7 |
Abbreviations: APT, aggressive pituitary tumor, IHC, immunohistochemistry; PC, pituitary carcinoma.
a Somatotrophs (4); silent Pit 1 positive (3); double TSH/FSH (1); null cell PitNET (1).